Earnings - 31st March 2009

6:47PM Celgene sees Q1 revs below consensus, reaffirms FY09 EPS and revs below consensus, co expects to achieve FY09 results at the lower end of ranges (CELG)44.40 -0.95 : Co issues downside guidance; co sees Q1 revs of ~$600 mln vs $647.1 mln First Call consensus. Co reaffirms FY09 EPS of $2.05-2.15 vs $2.16 consensus, sees revs of $2.6-2.7 bln vs $2.77 bln consensus. The co expects to achieve results at the lower end of these ranges. CELG is targeting REVLIMID product sales in 2009 to increase to ~$1.7 bln, driven by initiatives to expand its worldwide commercial potential, continued global market share gains and longer treatment durations. The co anticipates that VIDAZA sales will nearly double to ~$400 mln. The co reaffirms its five year outlook as it believes the aggressive global expansion of its hematology and oncology franchise, characterized by multiple product launches in various countries, combined with significant operating leverage, improving gross margins and tax rates, should facilitate top line growth of ~20% and bottom line growth of ~25-30%.

4:11PM Pervasive Sftwr raises Q3 guidance (PVSW) 3.90 +0.16 : Co issues upside guidance for Q3 (Mar), sees EPS of $0.10-0.11 up from $0.05-0.08 vs. $0.07 First Call consensus; sees Q3 (Mar) revs of $12.8-13.1 mln up from $10.5-11.5 vs. $11.14 mln consensus. The co expects to report positive cash flow from operations of approx $2.0 mln in the third quarter of fiscal 2009, ending the quarter with approx $44.0 mln in cash and marketable securities. Pervasive acquired approx 733,000 shares of Pervasive common stock on the open market at a total cost of approx $2.7 mln, or approx $3.72 weighted average price per share, during the quarter ended March 31, 2009. The co has $10 mln authorized repurchase funds remaining under its $10.0 mln stock repurchase program announced in March 2009. Depending on market conditions and other factors, such purchases may be commenced or suspended at any time without prior notice. Issued and outstanding shares of common stock as of March 31, 2009 totaled approx 18.2 mln

4:04PM Apollo Group beats by $0.12, beats on revs (APOL) 78.33 -0.61 : Reports Q2 (Feb) earnings of $0.77 per share, $0.12 better than the First Call consensus of $0.65; revenues rose 26.3% year/year to $876.1 mln vs the $865.5 mln consensus. Co report 20.4% year-over-year increase in University of Phoenix total Degreed Enrollment to 397,700.

11:31AM Alliant Tech acquires Eagle Industries; expects the acquisition to add more than $80 mln to FY10 revenues and slightly accretive to FY10 EPS (ATK) 66.38 +2.38 : Co has acquired Eagle Industries, as it expands its position in the domestic and international tactical accessories markets serving military and law enforcement customers. While terms of the agreement were not disclosed, co expects the acquisition to add more than $80 mln to FY10 revenues, and be slightly accretive to FY10 earnings per share (EPS). Eagle Industries will become part of ATK's Armament Systems group.